AU737287B2 - Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 - Google Patents

Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 Download PDF

Info

Publication number
AU737287B2
AU737287B2 AU58195/98A AU5819598A AU737287B2 AU 737287 B2 AU737287 B2 AU 737287B2 AU 58195/98 A AU58195/98 A AU 58195/98A AU 5819598 A AU5819598 A AU 5819598A AU 737287 B2 AU737287 B2 AU 737287B2
Authority
AU
Australia
Prior art keywords
copolymer
administered
inhalation
ingestion
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU58195/98A
Other languages
English (en)
Other versions
AU5819598A (en
Inventor
Ruth Arnon
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Michael Sela
Dvora Teitelbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU5819598A publication Critical patent/AU5819598A/en
Application granted granted Critical
Publication of AU737287B2 publication Critical patent/AU737287B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AU58195/98A 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 Expired AU737287B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL119989 1997-01-10
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
AU5819598A AU5819598A (en) 1998-08-03
AU737287B2 true AU737287B2 (en) 2001-08-16

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58195/98A Expired AU737287B2 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Country Status (18)

Country Link
EP (1) EP0975351B1 (cg-RX-API-DMAC7.html)
JP (1) JP4216342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20000070058A (cg-RX-API-DMAC7.html)
CN (1) CN100528222C (cg-RX-API-DMAC7.html)
AT (1) ATE356608T1 (cg-RX-API-DMAC7.html)
AU (1) AU737287B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI9807076B8 (cg-RX-API-DMAC7.html)
CA (1) CA2277365C (cg-RX-API-DMAC7.html)
CZ (1) CZ297983B6 (cg-RX-API-DMAC7.html)
DE (1) DE69837324T2 (cg-RX-API-DMAC7.html)
EA (1) EA003128B1 (cg-RX-API-DMAC7.html)
HU (1) HU226612B1 (cg-RX-API-DMAC7.html)
IL (2) IL119989A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ336690A (cg-RX-API-DMAC7.html)
PL (1) PL193300B1 (cg-RX-API-DMAC7.html)
SK (1) SK284029B6 (cg-RX-API-DMAC7.html)
WO (1) WO1998030227A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA98214B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
CA2375874A1 (en) * 1999-06-04 2000-12-14 Chris Polman Use of riluzole for the treatment of multiple sclerosis
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
JP2007521249A (ja) * 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
EP0975351A4 (en) 2002-05-15
EP0975351A1 (en) 2000-02-02
PL193300B1 (pl) 2007-01-31
PL334566A1 (en) 2000-03-13
BR9807076B1 (pt) 2013-10-29
WO1998030227A1 (en) 1998-07-16
HUP0001917A2 (hu) 2000-10-28
CN1249690A (zh) 2000-04-05
CA2277365C (en) 2011-04-12
EA199900621A1 (ru) 2000-02-28
IL119989A0 (en) 1997-04-15
CZ297983B6 (cs) 2007-05-16
ATE356608T1 (de) 2007-04-15
AU5819598A (en) 1998-08-03
SK93199A3 (en) 2000-11-07
JP4216342B2 (ja) 2009-01-28
EP0975351B1 (en) 2007-03-14
IL130820A (en) 2007-03-08
SK284029B6 (sk) 2004-08-03
KR20000070058A (ko) 2000-11-25
HUP0001917A3 (en) 2001-12-28
CA2277365A1 (en) 1998-07-16
HK1025737A1 (en) 2000-11-24
BR9807076A (pt) 2000-05-02
BRPI9807076B8 (pt) 2021-05-25
HU226612B1 (en) 2009-04-28
DE69837324T2 (de) 2007-11-29
DE69837324D1 (de) 2007-04-26
NZ336690A (en) 2001-05-25
CN100528222C (zh) 2009-08-19
ZA98214B (en) 1999-08-11
CZ243799A3 (cs) 2000-06-14
JP2001511121A (ja) 2001-08-07
EA003128B1 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
US6214791B1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
CA2277365C (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998030227A9 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
KR100239743B1 (ko) 인슐린을 함유하는 타입 1 당뇨병 치료용 경구투여, 장내투여 또는 흡입경구투여용 제제
JP3712260B2 (ja) 自己免疫疾患のバイスタンダー抑制
AU742970B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
AU2010260585B2 (en) Compositions and methods for treatment of Multiple Sclerosis
NO314878B1 (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av reumatoid artritt og multippel sklerose
WO1996039176A1 (en) USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
KR100435040B1 (ko) 티세포매개성질환들의치료를위한제제들및방법들
CN107582566A (zh) 通过多胺化合物调控自身免疫性疾病的方法和组合物
HK1025737B (en) Treatment of multiple sclerosis through ingestion of copolymer-1
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
US11400131B2 (en) Multi-peptide composition
CA2984957C (en) Multi-peptide composition
JP2003512435A (ja) 予防及び治療方法
HK1167101B (en) Compositions and methods for treatment of multiple sclerosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)